Cluster-Randomized Trials — Insights from Cardiovascular Prevention
AbstractCluster-randomized trials are increasingly relevant to the evaluation of preventive and treatment strategies for chronic disease, especially when interventions are delivered through groups, practices, communities, or health systems rather than individuals. Using cardiovascular prevention as an illustrative example, we review key design, conduct, and analytic issues that determine when cluster randomization is appropriate and how such trials should be designed, analyzed, and interpreted. Particular attention is given to the choice of the unit of randomization, protection of internal validity, implications for statistical efficiency, and alignment of outcomes and analyses with the level and mechanism of intervention delivery. A clear understanding of these principles should strengthen the design, interpretation, and policy relevance of cluster-randomized trials.
Authors
- Borja Ibáñez (ORCID: https://orcid.org/0000-0002-5036-254X)
- Valentı́n Fuster (ORCID: https://orcid.org/0000-0002-9043-9986)
- Ravi Vazirani
- Deepak L. Bhatt
Institutions
- Spanish National Centre for Cardiovascular Research (ES)
- Mount Sinai Hospital (US)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Universidad Autónoma de Madrid (ES)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2026-08-25
- DOI
- https://doi.org/10.1056/evidctw2600148
- Primary Topic
- Advanced Causal Inference Techniques
- Type
- article
- Field-Weighted Citation Impact
- 0.00